Table 2.

Summary of outcomes of included studies

Outcome measures	Measurements	Results
Rate of symptomatic hemorrhage	Baseline and after-treatment variables with symptomatic and asymptomatic	Following treatment with tenecteplase, there was a greater early clinical improvement with a median of 9 in comparison to alteplase’s median of 1 [13].
	National Institutes of Health Stroke Scale score (NIHSS)	No significant difference between both scores because a majority of the score range fell between 0 and 4 for both interventions [16].
Functional outcome at 90 days	Modified Rankin Scale (mRS)	Both interventions shared the same effect [12, 16].
		A higher proportion of patients showed a significant recovery using the tenecteplase intervention [15].
		The proportion of patients with good functional outcome was 61% in the tenecteplase group and 57% in the alteplase group (odds ratio, 1.24; 95% CI 0.65–2.37).
Reperfusion rate after thrombectomy	Modified thrombolysis in cerebral infarction (mTICI)	Over the course of 90 days following the treatment, overall reperfusion rates were significantly higher than alteplase [13].
		Tenecteplase was associated with significantly better reperfusion (P=0.004) and clinical outcomes than alteplase (P<0.0001) [15].